News Archive

CardioHealth Alliance welcomed Novo Nordisk Inc. to the CardioHealth Alliance group on March 9, 2023, aiming to expedite evidence-based solutions for prevention and care of cardiovascular, renal and metabolic cardio-metabolic diseases.

The HEAL Connections team – led by DCRI faculty Asheley Skinner, PhD (Population Health) and Rachel Greenberg, MD, MB, MHS, and Christoph Hornik, MD, PhD, MPH (Pediatrics) – partnered with the North Carolina Harm Reduction Coalition (NCHRC) to make naloxone kits on March 21 as an opportunity to connect in-person and learn more about community efforts to stop overdose deaths. 

At the DCRI, we’re bringing creative solutions to the world’s most vexing health problems.

A consortium called the CardioHealth Alliance brings together a multi-disciplinary group of experts to improve the care and health of patients across cardiovascular, renal and metabolic diseases.

DCRI faculty and staff took part in more than 80 events at the 2023 American College of Cardiology Scientific Sessions (ACC.23), paired together with the World Congress of Cardiology (WCC). Events included late-breaking and featured presentations, panel discussions, debates, mentorship events, and moderated poster sessions. They covered topics ranging from interventional therapies, drug comparisons, to guideline adherence and preventive care.

The COVID Treatment Quick Start Consortium announced today that the governments of Zambia, Laos, Malawi and Rwanda have received shipments of PAXLOVID™ (nirmatrelvir/ritonavir), Pfizer’s COVID-19 oral treatment. Partners involved in the Quick Start Consortium are supporting test-and-treat programs to improve access to antiviral treatments in low- and middle-income countries.

Patients who have diabetes and heart disease do best when both conditions are treated according to established guidelines, but far too many are not prescribed the effective therapies. A recent study — designed and led by the Duke Clinical Research Institute (DCRI) and an academic steering committee — found that a coordinated care approach between cardiologists and diabetes specialists resulted in more patients receiving the recommended therapies. The study was funded by Boehringer Ingelheim and Eli Lilly and Company.

Duke Clinical Research Institute cardiovascular faculty member Stephen Greene, MD, joins Brigham and Women’s cardi

A recent trial of empagliflozin expanded the understanding of how the drug can slow chronic kidney disease in a wide range of patients, lowering the risk of disease progression and death from cardi

Duke Clinical Research Institute builds a lasting tradition around celebrating milestone moments